Y-4 tables
Phase 2Small molecule
Y-4 tables is one of 55 small molecule programs targeting Tics. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
CAB LA
GSKPhase 2
Tylenol
KKenvue Brands
Phase 1
Rifampicin
Boehringer IngelheimPhase 1
Tarceva
OOSI Pharmaceuticals
Phase 1
Abexinostat
XXynomic Pharmaceuticals, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tics1 trial
Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Recruiting·—·Phase 1·NCT06935682·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Y-4 tables. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details